pharmaceuticals

Popular Today
Popular Today
Popular All Time
Newest
Charts and Videos
Charts and Videos
Charts
Videos
bhowe bhowe LABU, 1D, Long ,
207 2 6
LABU, 1D Long
LABU long idea

LABU setting up for another run higher? Indicators would suggest it. Buy the dip...........

Dario1987 Dario1987 ALXN, 1D, Long ,
17 0 1
ALXN, 1D Long
Alexion (AXLN): new entry long

Time to raise up the head has come for ALexion pharmaceuticals. After some years in a trading range and a never ending downtrend since 2015 (black line) price has broken it up reaching recently 135.87 dollars. As showned in the graph we have an important technical signal which is the cross between MA 50 and MA 200. We have also the RSI confirming tghe momentum and ...

Keep-it-Real Keep-it-Real 4578, 1D, Long ,
9 0 1
4578, 1D Long
LONG TERM LONG ON OTSUKA PHARMA!

I will not go into details on this one. Bottom line is, I am impressed with Otsuka's vision and its recent developments - and many other things which I will not explain here. I will be entering a long position soon, watching the action at these levels. This is will be one of the stocks I would recommend to add to your stocks portfolio. -Keep it Real-

micahdonovick micahdonovick BIIB, D, Short ,
36 0 1
BIIB, D Short
Biogen Earnings Swing July 2018

Biogen's (344.10 at close at the date of this writing) and Eisai's recent success with BAN24O1, an experimental medication for Alzheimer's which is currently in mid-stage clinical trials, in addition to a recent price target raise by Citi, and overall bullish analyst sentiment led to a rally between July 6-9, 2018. Although the clinical trial's success was ...

71 0 1
ATNX, 720
ATNX to retest Support high 17's to mid 18's

ATNX may be a tad over extended for now and will likely retrace to it's 18.50 or high 17's support area. May look for a buy in here. ANTX recently named Timothy Cook as senior vice president of global commercial oncology. This is recent add to an all star team in the oncology pharma space. I see a bright future for this asset. ***Any information represented ...

14 0 1
LPCN, 240
Playing the gap with pharmaceuticals, Lipocine Inc (LPCN)

Pharmaceuticals can take nasty falls if their products fail to pass FDA muster. These falls can provide nice opportunities for swing traders to play the gaps that are left by these sharp moves of price action. Lipocine Inc (LPCN) took a nasty dive on the 8th of May, leaving behind a pretty nice 31% gap that will eventually get filled. Since the drop, LPCN has ...

GPI-Legacy GPI-Legacy SNDX, 1D, Long ,
19 0 1
SNDX, 1D Long
SNDX - Syndax Pharmaceuticals - Loyal to the base bounce?

First of all, I'm in love with this chart, not like a friend, but like a secret admirer whilst in high school going thru my hormonal changes. Syndax Pharmaceuticals has consistently shown great loyalty to the bounce when it reaches lower levels, close to or under it's support. This Pharma stock has shown to have great support at about $8.00. SNDX has a couple ...

62 2 3
CELG, 1D
Celgene is under the radar

Celg is under the radar because after an insane downtrend, calm and a bit of optimism is getting back. Price is consolidating in a narrow range and on friday we have seen a first endeavour to break the flag with no success. This has happend because MA 50 has acted like a resistence. If the price breaks the wall of 80/80.50 with momentum I expect a new buy long ...

Dario1987 Dario1987 TEVA, 1D, Long ,
82 0 1
TEVA, 1D Long
TEVA up trend is accelerating

As showed in the picture trend is accelerating as a sign of streght for TEVA. After some consolidation pauses we have a situation where RSI in pointing up, MACD non really clear as we have had a lateral movement, volatility stop positive. Red trendline is showing the acceleration. TP around 27 first and 30 dollars after. Despite some up and down of nasdaq, Teva ...

60 0 3
GSK, W Short
GlaxoSmithKline Short

Short from $42.01. - Market Cap: $102B - Beta: 0.83 - P/B: 20.42 - GSK’s consumer healthcare segment sales were down in 2017 due to a slowdown in global growth of its key consumer categories. - They have also faced pricing pressure from competition and slow down in emerging markets. Although GSK have several candidates in different stages of development, the ...

dvdgege5 dvdgege5 ABBV, 1D, Long ,
116 0 2
ABBV, 1D Long
ABBV - when having all your eggs in one basket works out

AbbVie's bread winner is Humira - this drug accounts for the majority of their revenue. However, they did forecast that by 2020, revenue from Humira will be $21B - which is about 75% of their 2017 revenue of $28.22B. Since AbbVie depends so heavily on their flagship, their stock is fairly volatile, giving this play more of a risk. Consider well-hedged positions ...

Dario1987 Dario1987 TEVA, 1D, Long ,
86 0 4
TEVA, 1D Long
Teva is now a buy

After a couple of years where price has persistently followed the downtrend, last week Teva broke up such dynamic hreshold. Price has confirmed such trendline with a hammer 3 days ago at 17.04 dollars. Moreover we have the cross on the daily pattern between MA 50 and MA 200 turning to bullish set-up. Q1 earnings has been released beating expectations. SAR is ...

mazuralexander1 mazuralexander1 VSTM, 1D, Long ,
74 0 3
VSTM, 1D Long
VSTM to the Moon

Vstm is developping a cure for lukeimia

Dario1987 Dario1987 MYL, 1D, Long ,
16 0 2
MYL, 1D Long
MYL a buy opportunity

After the breach of the multiyears downtrend prices have jumped till 47.68 dollars. We have seen a retracement according to the uptrend in progress. The price level around 39-40 is a stong support where a long can be setup. SL can be put a bit lower just underneath the MA 200 at 38 dollars. MA 200 is still under MA 50 and MACD is crossing over for a bullish ...

7032 0 1
AKER, D
Aker still in good position

Aker still in a great position with an awesome balance sheet.

139 0 2
ANTH, 60
Anthera Pharmaceutical ... -80%

This is biotech "at its best". An expert review board gave this drug an approval of passing, with a shelf offering of about $100 millions. And now ... Sollpura has just failed to achieve the desired results in a Phase 3 clinical study ... Luckily, I closed one trade with a win for this stock. Conclusion: Stay away from small biotech firms!

dustyPH dustyPH GWPH, 240, Long ,
81 0 4
GWPH, 240 Long
Shaping the Future - an analysis on GWPH

Good Afternoon and welcome to an analysis on GWPH. Looking at the chart we can see that GWPH broke through the support line on 2/22 and is now testing it as the current Major Resistance line. We have fallen to the Major Support line on 3/2 and bounced back up to touch the resistance line again. We almost looked as though we were going to break into the ...

284 1 4
TEVA, 1D
$TEVA - Berkshire breakout?

Disclaimer, TEVA is in a very bad financial position, with dwindling cashflows and large debt. Buffet has always been the king of "value investing", hence why a position in Teva isn't surprising from him - it's most likely that he sees the company as severely undervalued and is entering into stages of repair. Buffet's new position in Teva was widely publicised ...

Show More Ideas 12345
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out
Browse
Video